News
Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’
Janssen has reported new data for its B-cell maturation antigen (BCMA) directed CAR T therapy ciltacabtagene autoleucel (cilta-cel) in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients.